Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma-Reference-Cited by-同舟云学术

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Published:2018-02-22 Issue:8 Volume:131 Page:888-898
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Horwitz Steven M.¹,Koch Raphael²³^ORCID,Porcu Pierluigi⁴^ORCID,Oki Yasuhiro⁵,Moskowitz Alison¹,Perez Megan¹,Myskowski Patricia¹^ORCID,Officer Adam⁶,Jaffe Jacob D.⁶^ORCID,Morrow Sara N.²³,Allen Kerstin⁷,Douglas Mark⁷,Stern Howard⁷,Sweeney Jennifer⁷,Kelly Patrick⁷,Kelly Virginia⁷,Aster Jon C.⁸³^ORCID,Weaver David⁹,Foss Francine M.¹⁰,Weinstock David M.²³⁶^ORCID

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY;

2. Dana-Farber Cancer Institute, Boston, MA;

3. Harvard Medical School, Boston, MA;

4. The Ohio State University Comprehensive Cancer Center, Columbus, OH;

5. MD Anderson Cancer Center, Houston, TX;

6. Broad Institute of Harvard and MIT, Cambridge, MA;

7. Infinity Pharmaceuticals Inc., Cambridge, MA;

8. Brigham and Women’s Hospital, Boston, MA;

9. Verastem Pharmaceuticals, Needham, MA; and

10. Yale University Cancer Center, New Haven, CT

Abstract

Key Points The oral PI3K-δ,γ inhibitor duvelisib demonstrated clinical activity and a favorable safety profile in patients with CTCL and PTCL. Duvelisib induced cell-autonomous killing of TCL lines and reprogrammed PTCL-associated macrophages in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/8/888/1466752/blood802470.pdf

Reference44 articles.

1. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood,2011

2. Peripheral T-cell lymphoma;Foss;Blood,2011

3. How I treat the peripheral T-cell lymphomas;Moskowitz;Blood,2014

4. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors;Mak;J Clin Oncol,2013

5. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study;O’Connor;J Clin Oncol,2011

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of biomimetic nanoparticles for macrophage repolarisation and phagocytosis in tumour immunotherapy;Chemical Engineering Journal;2024-10

2. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy;Mini-Reviews in Medicinal Chemistry;2024-09

3. Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer;Bioactive Materials;2024-09

4. Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma;Kinases and Phosphatases;2024-08-28

5. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10